Risk of prostate cancer in patients with schizophrenia

Comprehensive Psychiatry

Volumn 55, Issue 7, 2014, Pages 1639-1642

  Raviv, Gil ^a,c   Laufer, Menachem ^a,c   Baruch, Yehuda ^b,c   Barak, Yoram ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b ABARBANEL MENTAL HEALTH CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ADULT; ARTICLE; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; COHORT ANALYSIS; COMPARATIVE STUDY; HUMAN; HYPERPROLACTINEMIA; ISRAEL; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; PROSTATE CANCER; SCHIZOPHRENIA; SEX DIFFERENCE; TERTIARY HEALTH CARE; AGED; COMPLICATION; HOSPITAL PATIENT; LUNG TUMOR; MIDDLE AGED; PROSTATE TUMOR; REGISTER; RISK; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; HUMANS; INPATIENTS; ISRAEL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; REGISTRIES; RISK; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84907737015     PISSN: 0010440X     EISSN: 15328384     Source Type: Journal    
DOI: 10.1016/j.comppsych.2014.05.007     Document Type: Article

References (28)

1. J.A. Pandiani, M.M. Boyd, and S.M. Banks Elevated cancer incidence among adults with serious mental illness Psychiatr Serv 57 2006 1032 1034
2. Y. Barak, T. Levy, and A. Achiron Breast cancer in women suffering from serious mental illness Schizophr Res 102 2008 249 253
3. V.S. Catts, S.V. Catts, and B.I. O'Toole Cancer incidence in patients with schizophrenia and their first-degree relatives - a meta-analysis Acta Psychiatr Scand 117 2008 323 336
4. S. Alessi-Severini, R.G. Biscontri, and D.M. Collins Utilization and costs of antipsychotic agents: a Canadian population-based study, 1996-2006 Psychiatr Serv 59 2008 547 553
5. D.L. Leslie, S. Mohamed, and R.A. Rosenheck Off-label use of antipsychotic medications in the department of Veterans Affairs health care system Psychiatr Serv 60 2009 1175 1181
6. G.C. Alexander, S.A. Gallagher, and A. Mascola Increasing off-label use of antipsychotic medications in the United States, 1995-2008 Pharmacoepidemiol Drug Saf 20 2011 177 184
7. C.H. Miller, F. Mohr, and D. Umbricht The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone, and conventional antipsychotics J Clin Psychiatry 59 1998 69 75
8. D.B. Allison, J.L. Mentore, and M. Heo Antipsychotic-induced weight gain: a comprehensive research synthesis Am J Psychiatry 156 1999 1686 1696
9. J.R. Bostwick, S.K. Guthrie, and V.L. Ellingrod Antipsychotic-induced hyperprolactinemia Pharmacotherapy 29 2009 64 73
10. B.L. Harlow, D.W. Cramer, and J.A. Baron Psychotropic medication use and risk of epithelial ovarian cancer Cancer Epidemiol Biomarkers Prev 7 1998 697 702
11. P.S. Wang, A.M. Walker, and M.T. Tsuang Dopamine antagonists and the development of breast cancer Arch Gen Psychiatry 59 2002 1147 1154
12. K. Yamazawa, H. Matsui, and K. Seki A case-control study of endometrial cancer after antipsychotics exposure in premenopausal women Oncology 64 2003 116 123
13. S. Wagner, and N. Mantel Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents Cancer Res 38 1978 2703 2708
14. L. Azoulay, H. Yin, C. Renoux, and S. Suissa The use of atypical antipsychotics and the risk of breast cancer Breast Cancer Res Treat 129 2011 541 548
15. E.F. Torrey Prostate cancer and schizophrenia Urology 68 2006 1280 1283
16. J. Hippisley-Cox, Y. Vinogradova, and C. Coupland Risk of malignancy in patients with schizophrenia or bipolar disorder: nested case-control study Arch Gen Psychiatry 64 2007 1368 1376
17. A. Nakamura, T. Shirai, and K. Ogawa Promoting action of prolactin released from a grafted transplantable pituitary tumor (MtT/F84) on rat prostate carcinogenesis Cancer Lett 53 1990 151 157
18. F.G. Robertson, J. Harris, and M.J. Naylor Prostate development and carcinogenesis in prolactin receptor knockout mice Endocrinology 144 2003 3196 3205
19. K. Dillner, J. Kindblom, and A. Flores-Morales Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate Endocrinology 144 2003 4955 4966
20. P. Lissoni, A. Bignami, and L. Frontini Possible involvement of prolactin in endocrine-resistant metastatic prostate cancer Int J Biol Markers 20 2005 123 125
21. P. Stattin, S. Rinaldi, and U.H. Stenman Plasma prolactin and prostate cancer risk: a prospective study Int J Cancer 92 2001 463 465
22. A.B. Sabin Proceedings: cancer research in Israel: work of academic institutions and National Cancer Registry Natl Cancer Inst Monogr 40 1974 57 62
23. G. Yovel, P. Sirota, D. Mazeh, G. Shakhar, E. Rosenne, and S. Ben-Eliyahu Higher natural killer cell activity in schizophrenic patients: the impact of serum factors, medication, and smoking Brain Behav Immun 14 2000 153 169
24. B.J. Kinon, J.A. Gilmore, H. Liu, and U.M. Halbreich Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone Psychoneuroendocrinology 13 Suppl. 2 2003 55 68
25. S. Smith, M.J. Wheeler, R. Murray, and V. O'Keane The effects of antipsychotic-induced hyperprolactinaemia on the hypothalamic-pituitary-gonadal axis J Clin Psychopharmacol 13 2002 109 114
26. K. Berinder, O. Akre, and F. Granath Cancer risk in hyperprolactinemia patients: a population-based cohort study Eur J Endocrinol 165 2011 209 215
27. S.O. Dalton, C. Johansen, and A.H. Poulsen Cancer risk among users of neuroleptic medication: a population-based cohort study Br J Cancer 95 2006 934 939
28. P.B. Mortensen Neuroleptic medication and reduced risk of prostate cancer in schizophrenic patients Acta Psychiatr Scand 185 1992 390 393